DCC Plc Trades Steady at 6,130p After KKR Bids £5.7 Billion, July in Focus

DCC Plc Trades Steady at 6,130p After KKR Bids £5.7 Billion, July in Focus

June 12, 2026

London, June 12, 2026, 14:09 (BST)

  • DCC Plc held steady at 6,130p after the board backed a new offer from KKR and Energy Capital Partners. Shares didn’t move.
  • The bid would put DCC’s value at 6,672.22p a share, made up of 6,525p cash plus a suggested 147.22p final dividend.
  • The next big move comes July 8. That’s the deadline for the consortium to put in a binding offer or step back, as required by Irish takeover rules.

DCC Plc traded at 6,130p by early Friday afternoon, holding steady after the FTSE 100 name signaled more progress toward a deal with a KKR- and Energy Capital Partners-led group. Shares moved between 6,115p and 6,170p in the session, according to Davy market data.

DCC on June 10 set out a new offer for shareholders, saying they would get 6,672.22p a share, with 6,525p in cash and a final dividend of 147.22p per share for the year ended March 31, 2026. The company said this revised offer was about 33% over the three-month volume-weighted average share price of 5,005p before talks started, and stands 15% higher than DCC’s earlier proposal of 5,800p per share that was turned down in April.

DCC shares are now acting like a merger-arb trade instead of a regular equity call on the business. The stock is at 6,130p, below both the 6,525p cash piece and the 6,672.22p stated deal value. So there is still a spread for those taking the risk that the deal closes. For buyers not getting the final dividend, the gap is tighter. DCC went ex-dividend May 28, with payout set for July 23, per market data.

Put-up-or-shut-up has been pushed back again. The Irish Takeover Panel moved the deadline for a bidder to make a firm offer or walk away to 5:00 p.m. London time on July 8, 2026. DCC reiterated there’s still no guarantee of any offer and that’s why the stock trades below the would-be deal price.

For the bulls, the board says it would be ready to recommend the financial terms if the consortium makes a formal bid at the same price. DCC’s core business is seen as still having strategic value. The company calls itself a multi-energy sales and distribution group, with operations in 12 countries and 10 million customers. Energy Products brings in 73% of EBITA, Mobility adds 24%. EBITA stands for earnings before interest, tax and amortisation, stripping out some financing and accounting costs.

Bears say the story now is about whether the deal happens, not whether the shares are cheap. Shares may lose the takeover premium if KKR and Energy Capital Partners walk away without a firm offer. Analyst upside also looks thin at this price. Investors Chronicle/LSEG data shows a median 12-month target of 6,100p from 11 analysts—just under the current 6,130p. The split: one Buy, seven Outperform, three Hold, zero Sells.

DCC trades at what looks like full or even slightly risky value for buyers coming in now, unless they’re only targeting the takeover spread. Investors could see gains if a formal offer comes in at 6,525p in cash, or up to 6,672.22p for those eligible. But the risk-reward here is mainly tied to the July 8 deadline, who can claim the dividend, and whether DCC still plans to sell its Technology business by end-2026 if the deal falls through.

Stock Market Today

  • GSK Shares Rise on Orphan Drug Status and $10.6 Billion Nuvalent Oncology Deal
    June 12, 2026, 9:13 AM EDT. GSK shares rose 1.32% after momelotinib earned Orphan Drug Designation from the US FDA and European Medicines Agency for VEXAS syndrome, a rare inflammatory disorder. This designation offers development incentives but does not authorize sales. The boost follows GSK's $10.6 billion acquisition of Nuvalent, adding late-stage lung cancer drugs zidesamtinib and neladalkib, with FDA decisions due by November 2026. GSK posted 5% sales growth in Q1 2026, driven by Specialty Medicines up 14% and oncology up 28%. The company aims for 3%-5% turnover growth and 7%-9% profit rise in 2026 but faces patent expiry and integration risks from the Nuvalent deal. Investors focus on upcoming ATLAS trial data and regulatory milestones for pipeline momentum.